Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 903 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07082686RecruitingPhase 2
A study of ICP-248 for mantle cell lymphoma that has come back or not responded
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
Hefei, AnhuiAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Birmingham, AlabamaAges 18 years+ - NCT07137637RecruitingPhase 1
HPB-092 for relapsed or refractory AML
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
TianjinAges 18 years+ - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+ - NCT03672721RecruitingPhase 1/Phase 2
Carboplatin with radiation for returning glioblastoma
This Phase 1/2 study tests a combination of carboplatin chemotherapy with radiation for glioblastoma that has come back. It aims to shrink or control the tumor after standard treatment has already been used.
Sherbrooke, QuebecAges 18 years+ - NCT03838926RecruitingPhase 1
Testing how safe and tolerable a new drug is for blood cancers
This Phase 1 study tests how safe and tolerable trichostatin A is in adults whose blood cancers have come back or did not respond to standard treatments. It may help researchers find an effective dose while monitoring side effects closely.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT03910738RecruitingPhase 2
Testosterone treatment for nerve protection and myelin repair in MS
This Phase 2 study tests whether taking testosterone (for low testosterone levels) can help protect nerves and repair myelin in people with relapsing-remitting multiple sclerosis (MS). It may be most relevant if your MS is stable and you have low blood testosterone without current androgen treatment.
BesançonAges 18–55 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT07027748RecruitingPhase 1
Testing a longer treatment of three drugs for neuroblastoma
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Boston, MassachusettsAges 1–30 - NCT04458688Recruiting
Ocrelizumab study for relapsing MS in African Americans and Caucasians
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Detroit, MichiganAges 18–60 - NCT04598399Recruiting
Mindfulness program for alcohol relapse prevention
This study compares two non-medication programs to help people with alcohol use disorder stay away from relapse. It tests whether mindfulness-based relapse prevention works better than relaxation meditation without a guide.
AngersAges 18 years+ - NCT04657861RecruitingEarly Phase 1
BCMA/TACI CAR-T for relapsed or refractory multiple myeloma
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT04684147RecruitingPhase 2
CNCT19 cell therapy for relapsed or refractory ALL
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Beijing, Beijing MunicipalityAges 18–65 - NCT04810624Recruiting
Online relapse prevention program for anorexia recovery habits
This study looks at how to help people with anorexia nervosa prevent relapse by changing habits, using video visits. It may help you stay stable after weight restoration and reduce the chance of returning to eating disorder symptoms.
New York, New YorkAges 18–60 - NCT04885569Recruiting
Therapy program to help prevent relapse in substance use
This trial tests a culturally adapted therapy combining motivational interviewing, CBT (talk-based skills therapy), and mindfulness to help people avoid relapse after detox. It may help you build coping tools and stay engaged in treatment.
LahoreAges 18 years+ - NCT04919538Recruiting
Long-term study of relapsing polychondritis
This study follows people who have been diagnosed with relapsing polychondritis over time. It aims to better understand the condition and how it progresses, which may help future care.
Philadelphia, PennsylvaniaAges Any age - NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT05079282RecruitingPhase 1
Study drug for relapsed or treatment-resistant T-cell lymphoma
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
Birmingham, AlabamaAges 18 years+ - NCT05105152RecruitingPhase 1
CAR T cell therapy for kids with CD33 AML that came back
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Seattle, WashingtonAges Up to 30 years - NCT05163301Recruiting
Alcohol relapse prevention for adults living with HIV
This study looks at ways to help people with HIV reduce the chance of heavy drinking coming back after a period of lower-risk drinking. It will use regular patient-reported check-ins about alcohol use to understand relapse patterns and test the approach’s impact.
Baltimore, MarylandAges 18 years+ - NCT05241093RecruitingPhase 2
HYML-122 plus cytarabine for FLT3-positive relapsed AML
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
Suzhou, JiangsuAges 18 years+
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 903 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.